Ways Ahead: developing a supported self-management programme for people living with low- and intermediate-grade gliomas - a protocol for a multi-method study.
adult oncology
health economics
neurological oncology
qualitative research
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
29 07 2020
29 07 2020
Historique:
entrez:
31
7
2020
pubmed:
31
7
2020
medline:
15
5
2021
Statut:
epublish
Résumé
Living with and beyond a diagnosis of a low- and intermediate-grade glioma (LIGG) can adversely impact many aspects of people's lives and their quality of life (QoL). In people with chronic conditions, self-management can improve QoL. This is especially true if people are supported to self-manage. Supported self-management programmes have been developed for several cancers, but the unique challenges experienced by LIGG survivors mean these programmes may not be readily transferable to this group. The Ways Ahead study aims to address this gap by exploring the needs of LIGG survivors to develop a prototype for a supported self-management programme tailored to this group. Ways Ahead will follow three sequential phases, underpinned by a systematic review of self-management interventions in cancer. In phase 1, qualitative methods will be used to explore and understand the issues faced by LIGG survivors, as well as the barriers and facilitators to self-management. Three sets of interviews will be conducted with LIGG survivors, their informal carers and professionals. Thematic analysis will be conducted with reference to the Theoretical Domains Framework and Normalisation Process Theory. Phase 2 will involve co-production workshops to generate ideas for the design of a supported self-management programme. Workshop outputs will be translated into a design specification for a prototype programme. Finally, phase 3 will involve a health economic assessment to examine the feasibility and benefits of incorporating the proposed programme into the current survivorship care pathway. This prototype will then be ready for testing in a subsequent trial. The study has been reviewed and approved by an National Health Service Research Ethics Committee (REC ref: 20/WA/0118). The findings will be disseminated through peer-reviewed journals, conference presentations, broadcast media, the study website, The Brain Tumour Charity and stakeholder engagement activities.
Identifiants
pubmed: 32727741
pii: bmjopen-2020-041465
doi: 10.1136/bmjopen-2020-041465
pmc: PMC7394298
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e041465Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Neuropsychol Rehabil. 2011 Jan;21(1):117-37
pubmed: 21154113
Psychooncology. 2015 Aug;24(8):940-9
pubmed: 25648410
Psychooncology. 2017 Feb;26(2):173-181
pubmed: 26537980
Patient Educ Couns. 2002 Oct -Nov;48(2):177-87
pubmed: 12401421
Oncol Nurs Forum. 2017 Nov 1;44(6):719-728
pubmed: 29052663
Psychooncology. 2008 Jun;17(6):621-5
pubmed: 17973236
Oncology (Williston Park). 2017 Sep 15;31(9):680-2, 684-5
pubmed: 29071695
J Psychosom Res. 2007 Dec;63(6):617-23
pubmed: 18061752
J Clin Oncol. 2015 Sep 1;33(25):2763-71
pubmed: 26169621
Psychooncology. 2015 Dec;24(12):1723-30
pubmed: 26014043
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Semin Oncol Nurs. 2018 Dec;34(5):472-485
pubmed: 30409554
Front Oncol. 2015 Jan 23;5:1
pubmed: 25667919
J Neurooncol. 1992 Nov;14(3):243-53
pubmed: 1460487
CMAJ. 2012 Apr 17;184(7):E373-82
pubmed: 22431898
J Med Internet Res. 2016 Aug 03;18(8):e210
pubmed: 27489143
BMC Med Res Methodol. 2019 Mar 12;19(1):55
pubmed: 30871474
Brain Inj. 2001 Oct;15(10):843-56
pubmed: 11595081
Int J Nurs Stud. 2013 May;50(5):587-92
pubmed: 23159157
Support Care Cancer. 2018 May;26(5):1585-1595
pubmed: 29199362
Ann Behav Med. 2013 Aug;46(1):81-95
pubmed: 23512568
BMJ. 2014 Mar 07;348:g1687
pubmed: 24609605
Neuro Oncol. 2014 Jul;16(7):896-913
pubmed: 24842956
J Neurooncol. 2013 Feb;111(3):355-66
pubmed: 23292152
J Neurooncol. 2002 Mar;57(1):41-9
pubmed: 12125966
Neuro Oncol. 2009 Jun;11(3):330-9
pubmed: 19001097
BMC Med. 2010 Oct 20;8:63
pubmed: 20961442
J Nurs Scholarsh. 2007;39(1):61-7
pubmed: 17393967
Lancet Oncol. 2008 Sep;9(9):884-91
pubmed: 18760244
Psychooncology. 2013 Jun;22(6):1299-305
pubmed: 22848038
BMC Public Health. 2014 Jul 15;14:719
pubmed: 25023948
BMC Fam Pract. 2019 Sep 4;20(1):122
pubmed: 31484493
Support Care Cancer. 2006 Nov;14(11):1094-103
pubmed: 16710653
Arch Sex Behav. 2012 Dec;41(6):1319-20
pubmed: 22968493
Stud Health Technol Inform. 2015;216:142-7
pubmed: 26262027
Implement Sci. 2011 Apr 23;6:42
pubmed: 21513547
Oncologist. 2014 Apr;19(4):403-13
pubmed: 24664484
Psychooncology. 2016 May;25(5):574-81
pubmed: 26804708
Palliat Med. 2001 Mar;15(2):127-34
pubmed: 11301663
BMJ Open. 2019 Aug 15;9(8):e029954
pubmed: 31420394
Neuro Oncol. 2012 Apr;14(4):392-404
pubmed: 22307475
Implement Sci. 2012 Apr 24;7:37
pubmed: 22530986
Neurosurg Focus. 2015 Jan;38(1):E6
pubmed: 25552286
Health Expect. 2016 Apr;19(2):194-208
pubmed: 25619975
Nutr Cancer. 2016 Jul;68(5):762-71
pubmed: 27176450
J Health Serv Res Policy. 2016 Apr;21(2):73-82
pubmed: 26377727
Psychooncology. 2017 Dec;26(12):2194-2200
pubmed: 28453887
CNS Oncol. 2014 Jan;3(1):37-47
pubmed: 25054899
Acta Neuropathol. 2005 Jan;109(1):93-108
pubmed: 15685439